New Reference: Maintenance Atezolizumab for Stage IB-IIIA NSCLC

Open-label, randomized, phase 3 trial (IMpower010)

Completely resected stage IB-IIIA NSCLC after adjuvant platinum-based chemotherapy

Atezolizumab (1,200 mg q3w for 16 cycles) vs. best supportive care

mDFS: 68.5 mos vs. 37.3 mos (atezolizumab vs. BSC) (HR: 0.70 [0.55–0.91]) (stage II-IIIA PD-L1 TC ≥1%)

mDFS: 65.6 mos vs. 47.8 mos (HR: 0.85 [0.71–1.01]) (intention-to-treat population)

mOS: NR vs. 87.1 mos (HR: 0.77 [0.56–1.06]) (stage II-IIIA PD-L1 TC ≥1%)

mOS: NR vs. NR (HR: 0.97 [0.78–1.22]) (intention-to-treat population)

Immune-mediated AEs: 52.1% vs. 9.7%

Felip E,Altorki N,Zhou C Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial

Reviewed by Ulas D. Bayraktar, MD on Jun 2, 2025